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A B S T R A C T
Aim: Dysmorphic neurons and balloon cells in focal cortical dysplasia (FCD) reportedly show immaturity
and abnormal differentiation with neuronal and glial components. Although normal-looking neurons
(NL-neurons) in FCD are major constituent elements, their biological characteristics have never been
identiﬁed. The aim of this studywas to investigate maturation of NL-neurons with the focus on neuronal
developmental lineage.
Methods: Eighteen FCD surgical specimens and controls were examined immunohistochemically using
the antibodies for nestin, mammalian achaete-scute complex homolog 1 (Mash1), prospero-related
homeobox 1 (Prox1), neuron-speciﬁc beta-III tubulin (Tuj1) and microtubule-associated protein 2
(MAP2) of neuronal lineage, glutamic acid decarboxylase (GAD), calretinin (CR) and calbindin (CB) of
interneuron markers, and glial ﬁbrillary-acidic protein (GFAP) of glial cell marker. Additionally, we
performed ﬂuorescent-double staining with these markers, and semi-quantitative analysis.
Results: NL-neurons in FCD had both mature and immature components, without interneuron
components. NL-neurons in FCD showed abnormal maturation with the combined expression of
MAP2 and Mash1/Prox1. Prox1-containing cell distribution in the deep layer was different from that of
Mash1-containing cells in the superﬁcial area. The MAP2-containing cell concentration decreased in the
order of type I-A, I-B, II-A and II-B, but the Tuj1-containing cell concentration increased.
Conclusion: These ﬁndings may reﬂect differences in neuronal function and expression timing in
developmental stages. From the standpoint of molecular expression, abnormal maturation of NL-
neurons may initiate synaptic dysfunction, resulting in intractable seizures of FCD.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Focal cortical dysplasia (FCD) is recognized as the major cause
of epilepsy in childhood. FCD was identiﬁed as a pathologic
substrate associated with epilepsy in 1971.1 The FCD pathology is
characteristically no laminar formation of the cortex with
disoriented and occasionally dysmorphic and/or balloon cells.2,3
FCD is pathologically divided into four subtypes.2 Interestingly,
each subtype has predominant location, mentality, epileptic
condition, imaging and surgical outcome.4,5 The most severe type
might be type II-B, although it shows the best surgical outcome.4,5* Corresponding author at: Department of Mental Retardation and Birth Defect
Research, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi,
Kodaira, Tokyo 187-8502, Japan. Tel.: +81 423461713; fax: +81 423461743.
E-mail address: itoh@ncnp.go.jp (M. Itoh).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.04.003The FCD pathogenesis is thought to be mainly embryonic
developmental insults and results in forming dysplastic lesions
with abnormal neuronal migration and differentiation.6 Balloon
cells in FCD type II-B are commonly identiﬁed with various stage
markers for neuronal maturation; nestin, b-tubulin III (Tuj1),
vimentin, and microtubule-associated protein 2 (MAP2), neuro-
ﬁlament, peripherin, and a-internexin.7 On the other hand, most
balloon cells have the combination of neuronal and glial
components, and expression of both MAP2 and glial ﬁbrillary-
acidic protein (GFAP).8 Dysmorphic cells reportedly express
mammalian achaete-scute homolog-1 (Mash1),9 which is a helix
loop-helix transcription factor expressed in progenitors.10 In the
early embryonic brain, Mash1-containing cells are recognized in
the neocortical subventricular zone, and at the next stage,
prospero-related homeobox 1 (Prox1)-expressed cells can be fated
to be a neuronal precursor.11 These facts indicate that dysmorphic
neurons and balloon cells in FCD remain immature or undifferen-
tiated. Many normal-looking neurons (NL-neurons) are usuallyvier Ltd. All rights reserved.
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balloon cells. In the present study, we attempted to conﬁrm that
NL-neurons in FCD were in the immature stages of neuronal
development.
2. Materials and methods
2.1. FCD surgical tissue preparation
Eighteen patients with drug-resistant epilepsy having FCD on
imagings participated in this study. Their clinical features are
summarized in Table 1. Studied samples were part of the tissues
removed for therapeutic reasons after careful assessment of the
epileptogenic areas, determined by analysis of seizure semiology,
electroencephalography, magnetic resonance imaging, ﬂuoro-
deoxyglucose positron emission tomography and ictal or interictal
single photon emission computed tomography. After resection,
hematoxylin and eosin (HE) and Klu¨ver-Barrera (KB) stainings
were done. The tissues diagnosed as FCD with no hippocampal
sclerosis by two individual neuropathologists were divided into 4
groups by Palmini’s classiﬁcation; type I shows abnormal cortical
lamination in the absence of dysmorphic neurons with giant or
immature neurons (type I-B) or neither (type I-A), while type II has
architectural abnormalities with dysmorphic neurons in the
presence of balloon cells (type II-B) or in the absence of those
cells (type II-A).2 For age-matched controls, we used brain tissues
of 5 healthy controls, who died suddenly and unexpectedly of
pneumonia and trafﬁc accidents at 1, 1.5, 6, 8 and 8.5 years of age,
without epilepsy and neuropathological changes. Brain tissues of
23 and 29 weeks gestation were used to conﬁrm nestin-, Tuj1-,
Mash1- and Prox1-immunoreactivities. Additionally, we added 3
tuberous sclerosis complex and 4 hemimegalencephaly patients as
disease controls. Informed consent to use the removed tissues for
this study was obtained from patients and controls or their
parents. This study was approved by the ethical committee of our
institute and hospital.
2.2. Normal-looking neurons
We deﬁned normal-looking (NL) neurons with no giant cell, no
dysmorphic neuron and no balloon cell, using HE and KB staining.
Many NL-neurons were observed in a FCD lesion, although the
characteristicmarker cells of FCDwere few in number in the lesion.
NL-neurons were small and round, or showed pyramidal neuron-
like features.
2.3. Immunohistochemistry
The serial sections were deparafﬁnized, rehydrated and pre-
treated in 0.3%H2O2 for 20 min to remove endogeneous peroxidase
activity. Heat-induced epitope retrieval was performed in sodium
citrate buffer solution (pH 6.0) by warming up to 95 8C in a
microwave oven for 10 min. Following blocking with 2% bovine
albumin in phosphate-buffered saline (PBS), the sections were
incubated at 4 8C for overnight with the antibodies. We used
monoclonal antibodies against MAP2 (dilution of 1:100; Sigma, St.
Louis, MO), Tuj1 (1:1000; R&D Systems Inc., Minneapolis, MN),
nestin (1:100; Chemicon International, Temecula, CA), glutamic
acid dehydroxylase (GAD) (1:1000; Biomole International, Ply-
mouth Meeting, PA), calretinin (CR) (1:1000; Sigma), calbindin
(CB) (1:1000; Sigma) and GFAP (1:1000; Sigma), as well as the
polyclonal antibodies against Prox1 (1:500; Sigma) and Mash1
(1:1000; kind gift of Dr. J.E. Johnson). As secondary antibodies,
horseradish peroxidase-labeled mouse-and-rabbit-IgG sera were
used (Nichirei, Tokyo, Japan). The antigen–antibody complex was
visualized with aminoethyl carbazole (Nichirei, Tokyo, Japan).Slide-mounted sections were counterstained with 0.2% methyl
green or hematoxylin. The stained sections were observed with a
microscope (BX50; Olympus, Tokyo, Japan), digitized with a
DXM1200F digital camera system (Nikon, Tokyo, Japan), and the
neuronal developmental lineage of NL-neurons in FCD was
evaluated.
2.4. Double labeling
To conﬁrm the relationship between the neuron and its
immaturity, double-labeling observation was performed with
MAP2, Mash1, Tuj1, GFAP and myelin basic protein (MBP; 1:200;
DAKO Corporation, Carpinteria, CA), as well as GAD, CR and CB.
Alexaﬂuor-488- and -568-conjugated secondary antibodies (Invi-
trogen Corporation, Carlsbad, CA) were applied for 1 h at room
temperature, and sections were mounted in a VECTASHIELD
mounting medium with DAPI (Vector Laboratories, Burlingame,
CA). The ﬂuorescent-stained sections were examined under a
ﬂuorescent microscope system (BX51 and BH2-RFL-T; Olympus)
and digitized by a DP70 system (Olympus).
2.5. Counts of immunopositive cells and their comparison between
FCD subtypes
Various immunopositivities of NL-neurons were observed in all
cases, and the number of cells was counted in each of 5 ﬁelds at a
magniﬁcation of 200 times. The number was corrected per 100
neurons in each case as the immunopositive cell concentration.
Four subtypes were analyzed.
For statistical analysis, the ANOVA testwas used for comparison
between the subtypes. Post hoc comparisons were done with
Fisher’s protected least-signiﬁcant difference test at a signiﬁcance
level of p < 0.05.
3. Results
All FCD lesions showed abnormal lamination of the cortices and
many ectopic neurons in the white matter (Fig. 1A). Our FCD series
was composed of ﬁve type I-A, ﬁve type I-B, ﬁve type II-A and three
type II-B. The immunohistochemistry is summarized in Table 1.
In age-matched controls, MAP2- or Tuj1-containing cells were
conﬁrmed in the cortex, but Mash1-, Prox1- and nestin-containing
cells were not (Table 1 and Fig. 2D1–D5, E1–E5). However, their
immunopositivities were conﬁrmed in fetal brains (Table 1 and
Fig. 2C1–C5). On the contrary, all FCD patients had diffusely Tuj1-
and MAP2-containing neurons in the cortices and white matter
(Figs. 1B, C and 2A1, A3). Tuj1-containing neurons were fewer than
those of MAP2-containing neurons. Mash1-containing neurons
distributed in the superﬁcial area of the cortex and white matter
(Fig. 1D). Interestingly, Prox1-containing neurons distributed in
the deep area of the cortex and white matter (Fig. 1E). Nestin-
containing cells were never observed (Fig. 2A2). GAD-, CR- and CB-
containing cells, which were interneurons, diffusely distributed in
the cortex, and became fewer in number (data not shown) as
previously reported.12,13
From the double staining, FCD revealed MAP2-containing cells
which had no glial features (Fig. 3A–F), but showed Mash1-
immunoreactivity (Fig. 3G–I). Tuj1-containing cells also had
Mash1-immunoreactivity (Fig. 3J–L). However, Mash1-containing
cells did not have GAD-, CR- or CB-immunoreactivities (data not
shown).
The number of immunopositive cells was estimated per 100
neurons after counting in 5 different ﬁelds. The numbers of MAP2-
containing cells were 77.4  10.5 (mean  standard deviation) in
control, 35.8  13.2 in type I-A, 23.0  10.1 in type I-B, 16.0  7.6 in
type II-A, and 10.2  5.0 in type II-B (Fig. 4). The numbers of
Table 1
Clinicopathological proﬁle of FCD patients.
Case Sex Age at surgery Age at
seizure onset
Seizure Intelligence FCD location
on imaging
Palmini’s
classiﬁcation
Other
neuropathology
Immunohistochemistry of NL-neurons
MAP2 GFAP MBP Nestin Tuj1 Mash1 Prox1
1 F 8M 1m CPS 47 (DQ) P+O I-A n.s.c. +    ++ + +
2 M 2Y 2m CPS+GTC 100 (IQ) P I-A Gliosis ++    + + 
3 F 3Y 3m CPS 50 (DQ) F I-A EN ++    + + 
4 M 6Y 4m CPS 33 (DQ) F I-A EN ++    + + +
5 M 7Y 11m CPS 58 (IQ) F I-A EN ++    ++ + +
6 M 6M 1m CPS 40 (DQ) P I-B EN, gliosis     ++ ++ +
7 M 2Y 20d CPS IS (DQ) F I-B CAL, EN ++    +  +
8 F 3Y 3m CPS 15 (DQ) P I-B Gliosis ++    ++ + 
9 F 10Y 4m CPS 45 (IQ) F I-B EN, gliosis ++    + + 
10 F 12Y 11m CPS 43 (IQ) F I-B Gliosis ++    + + 
11 F 3Y 6m CPS+GTC 40 (DQ) F+P II-A CAL, EN, gliosis +    ++ + 
12 F 5Y 2y 9m CPS 81 (IQ) F II-A Gliosis ++    + + +
13 M 6Y 3d CPS 16 (DQ) T+P+O II-A n.s.c. +    ++ + 
14 M 7Y 7m CPS 50 (IQ) P II-A CAL, EN, gliosis ++    ++ + +
15 M 10Y 1y 11m CPS+GTC 22 (IQ) F +T+P II-A CAL, EN ++    ++ + +
16 M 3Y 2y 9m CTC 15 (DQ) T+P+O II-B CAL, EN +    ++ + +
17 M 8Y 3m CPS+GTC 30 (IQ) F +P II-B CAL, EN, gliosis +    ++ + 
18 F 19Y 9m CPS+GTC 25 (IQ) P II-B CAL. EN, gliosis ++    ++  
TSC 1 F 7M CPS+GTC 65 (DQ) Diffuse cerebral cortex Cortical tuber ++    + + 
TSC 2 F 4Y CPS+GTC 50 (DQ) Diffuse cerebral cortex Cortical tuber ++    + + 
TSC 3 M 21Y CPS+GTC Under normal Diffuse cerebral cortex Cortical tuber ++    +  
HME 1 F 3M CPS+GTC 30 (DQ) rt-hemisphere PMG, CAL, EN ++    + + 
HME 2 F 3M CPS+GTC 35 (DQ) rt-hemisphere PMG, CAL, EN ++    + + 
HME 3 M 3M CPS+GTC 30 (DQ) lt-hemisphere PMG, CAL, EN ++    +  
HME 4 M 6M CPS+GTC 50 (DQ) lt-hemisphere PMG, CAL, EN ++      –
Control 23–29GW n.d. n.d. n.d. No n.s.c.    + ++ ++ ++
1–12M No Normal No No n.s.c. +    +  
1–8Y No Normal No No n.s.c. ++      
M, male; F, female; y, year(s); m, month(s); d, days; CPS, complex partial seizure; GTC, generalized tonic-clonk seizure; IQ, intelligent quotient; DQ, developmental quotient; P, parietal lobe; F, frontal lobe; O, occipital lobe; T,
temporal lobe; CAL, calciﬁcation(s); EN, ectopic neuron(s) in the white matter; n.d.: not described; n.s.c., no signiﬁcant changes; PMG: polymicrogyria; ++, observed immunopositive neurons; +, few immunopositive neurons;, no
immunopositive neurons; TSC; tuberous sclerosis complex; HME, hemimegalencephaly.
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Fig. 1. Immunohistochemistry of focal cortical dysplasia. In the FCD lesion of Case 15 (type II-A) in Table 1, cortical neurons are distributed at random (A). Large and
dysmorphic neurons are mainly observed in the deep area (B). Tuj1-immunopositive premature neurons are within the same distribution of MAP2-immunopositive neurons
(B and C). Interestingly, Mash1-immunopositive cells localize in the superﬁcial area (D), whereas Prox1-immunopositive cells are in the deep area andwhitematter (E). Insets
in C, D and E are large magniﬁcations of each rectangular region. Cx, cortex; WM, white matter; A, Klu¨ver–Barrera staining; B, MAP2-immunohistochemistry (IHC); C, Tuj1-
IHC; D, Mash1-IHC; E, Prox1-IHC. Scale bar is 500mm.
Fig. 2. Immunohistochemistry of neocortices of various malformed and normal developing brains. Normal-looking neuron of focal cortical dysplasia (FCD) expresses MAP2
(A1), Tuj1 (A3), Mash1 (A4) and Prox1 (A5), but not Nestin (A2). In tuberous sclerosis (TSC), MAP2 is expressed (B1) and Tuj1 is faintly positive (B3, arrows), but Nestin, Mash1
and Prox1 are negative (B2, B4, and B5). In early fetus brain, Nestin (C2), Tuj1 (C3), Mash1 (C4, arrows) and Prox1 (C5, arrows) are positive immunoreactivities, whereasMAP2
is negative (C1). In 1-month-old brain, MAP2 (D1) and Tuj1 (D3) are faintly immunostained (arrows), whereas Nestin (D2), Mash1 (D4) and Prox1 (D5) are negative. In
childhood, MAP2 (E1) is only immunopositive. Scale bars are 50mm.
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Fig. 3. Normal-looking neurons in focal cortical dysplasia and their abnormal maturation. MAP2-containing cells have no glial components of astrocyte (A–C) or
oligodendrocyte (D–F). MAP2-containing cells have Mash1-immunoreactivities (G–I). Many double-labeled cells with MAP2 andMash1 are visible (G). Tuj1-containing cells
haveMash1-immunoreactivities (J–L, arrows in L). All ﬁgures of the superﬁcial area of Case 15 (type II-A) are shown in Table 1. A, D and G, MAP2; B, GFAP; C, merged ﬁgure of
A and B; E, MBP; F, merged ﬁgure of D and E; H and K, Mash1; I, merged ﬁgure of G and H; J, Tuj1; L, merged ﬁgure of J and K. Scale bars indicate 25 mm.
Fig. 4. Distribution of immunopositive cells in each subtype.
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13.1 9.4 in type I-B, 21.3 15.7 in type II-A, and 33.1 6.1 in type II-
B. There were almost no Nestin-containing cells in all subtypes. The
numbers ofMash1-containing cellswere zero in control, 14.4 15.7 in
type I-A, 12.3 7.4 in type I-B, 13.4 13.8 in type II-A, and 12.0 17.9
in type II-B. The numbers of Prox1-containing cells were 0.2  0.4
in control, 3.2 4.6 in type I-A, 1.1 1.2 in type I-B, 5.8  11.9 in
type II-A, and 3.1  2.8 in type II-B. Statistical analysis revealed a
signiﬁcant difference of MAP2-containing cell concentration between
each subtype (p < 0.001 or p < 0.05) and the Tuj1-containing cell
concentration between types I and II (p < 0.001). The Prox1-containing
cell concentration showed a signiﬁcant difference between types I-B
and II-A (p < 0.05). Therewere no differences ofMash1-containing cell
concentration between each subtype.
4. Discussion
Although the examined cases were few, our results indicated
that NL-neurons in FCD had various developmental components
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interneuron components. MAP2- and Tuj1-containing cells were
distributed differently in every FCD subtype, although MAP2-
containing cell concentration signiﬁcantly decreased in all sub-
types, compared with control. This phenomenon may reﬂect
pathogenetic differences between FCD subtypes. Type I-A, I-B, II-A
and II-B show gradually severe clinical and pathological features.4,5
In this order, the MAP2-containing cell concentration decreased,
but the Tuj1-containing cell concentration increased. This may
indicate that many NL-neurons in type II-B are immature.
Dysmorphic neurons in FCD have been described as immature
and undifferentiated, having both neuronal and glial compo-
nents.14 The focus of the present study was the maturation of NL-
neurons in FCD. The biological characteristics of NL-neurons in
FCD have not been described, although they are major FCD
constituent elements. NL-neurons in FCD show morphologically
neuronal immaturity or abnormal migration.15 Recent molecular
neuroscience has explained mammalian neuronal lineage in
detail.16 In the ﬁrst stage of neuronal development, nestin
expresses in undifferentiated neuroepithelial cells.17 As nestin,
Mash1 also appears in neuronal progenitors in the neocortical
ventricular zone.11,18 Prox1, which expresses in the neocortical
subventricular zone, characterizes secondary precursor neu-
rons.11,19 Both Mash1- and Prox1-containing cells are mitotically
active and have transient proliferative potential.11 After the
disappearance ofMash1 and/or Prox1, Tuj1 (the earliestmarker of
postmitotic neuron) and MAP2 (the marker of mature neuron)
express in the cortical plate. In the current study,Mash1andProx1
were never observed in age-matched controls. Thus, these
transcriptional factors disappeared in the postnatal cortex. On
the basis of our results, it may be speculated that NL-neurons in
FCD can be characterized not only by their developmental
immaturity but also by expression of neuronal mature-markers
such as MAP2. In NL-neurons in FCD, both transcription factors
may have irregular functions, while Mash1 and Prox1 down-
stream genes are currently unknown. Although Mash1 obviously
induces a neuronal trait and plays an important role in neuronal
maturation, further study is warranted to understand the
molecular mechanism of the mixture of various developmental
stage markers in NL-neurons in FCD. Moreover, type II-A has a
relatively larger number of Prox1-containing cells than the other
types. This may reﬂect neuronal undifferentiation and lead to
neuronal dysmorphism.
Mash1 expresses in both projection neurons and interneurons.
To clarify which type of neuron Mash1 expressed in FCD, we
checked the colocalizations of Mash1 and MAP2/Tuj1, and Mash1
and GAD/CR/CB, interneuron markers. Mash1 colocalized with
MAP2 and Tuj1, but not with interneuron markers. This indicates
that Mash1-containing cells have immature projection neurons.
One can speculate that Mash1-containing cells of FCD may be
projection neurons and originate from neuronal precursors in the
neocortical ventricular zone.
Interestingly, Prox1-labeled cells exist in the neocortical
subventricular zone, the starting point for radial migration of
predictable pyramidal neurons.11 The Prox1-containing cell
distribution in the deep area of the cortex and white matter,
was different from that of Mash1-containing cells, predominantly
in the superﬁcial area of the cortex. This may reﬂect that both
labeled cells have a different function and birth timing.
In summary, epileptogenesis of FCD has been discussed in
terms of morphological abnormalities and dysfunction of synapse,
as well as the dysregulation of neuronal inhibition associated with
abnormal distribution of interneurons.20,21 Here, we provided dataon direct evidence for the dysmaturation of NL-neurons in FCD
from the standpoint of molecular expression. This maturational
abnormality may initiate synaptic dysfunction, resulting in
characteristic symptoms of FCD and intractable seizures.
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